Folakemi Odedina was named enterprise deputy director of community outreach and engagement at Mayo Clinic Cancer Center.
Stacy L. Palmer was named vice president of clinical administration and strategy at Winship Cancer Institute of Emory University.
Alex Parikh was named chief of surgical oncology and chair of the Mays Cancer Center Surgical Committee and Cancer Surgery Subservice Line at the Mays Cancer Center at UT Health San Antonio MD Anderson.
Erik Knudsen was named associate director of basic science research at Roswell Park Comprehensive Cancer Center. Knudsen will also continue as chair of Molecular and Cellular Biology.
Researchers at The University of Texas MD Anderson Cancer Center developed an approach to quantify tumor-specific total mRNA levels from patient tumor samples, which contain both cancer and non-cancer cells.
Mount Sinai researchers identified genes that predict a positive response to selinexor, a multiple myeloma therapy which can have serious side effects for some patients.
Researchers from the Dana-Farber Cancer Institute and the Tisch Cancer Institute at Mount Sinai Medical School showed that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care in 2021, although patient recruitment increased in 2021.
A multi-institutional study led by UNC Lineberger Comprehensive Cancer Center researchers found that diagnostic mammography results vary across racial and ethnic groups, with the rate of diagnostic accuracy highest in non-Hispanic white women and lowest in Hispanic women.
Results from the ELIANA pivotal clinical trial showed the long-term benefit of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with a maximum survival follow-up of 5.9 years.
Five-year follow-up results from the phase III CLL14 trial demonstrated that over 60% of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus Gazyva (obinutuzumab) continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment.
